CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
St John's wort induces the liver enzymes CYP3A4, CYP2B6, CYP2C9 and CYP2C19 and the transporter P-glycoprotein (St John's wort herbal monograph, European Medicines Agency, EMA). CYP3A enzymes are the main metabolic route for darunavir, and its boosters ritonavir and cobicistat inhibit CYP3A and so raise darunavir levels (darunavir summary of product characteristics, SmPC, EMA). According to the darunavir documents, St John's wort lowers the levels of darunavir, ritonavir and cobicistat, so human immunodeficiency virus (HIV) treatment may lose its effect and the virus may become resistant (darunavir SmPC, EMA, and darunavir label, US Food and Drug Administration, FDA). Darunavir boosted with cobicistat is more sensitive to this induction than darunavir boosted with ritonavir (EMA). The inducing effect may persist for at least 2 weeks after St John's wort is stopped (darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), although the herbal monograph says that enzyme activity returns to normal within 1 week (EMA).
Symptoms
The combination itself usually causes no symptoms: darunavir and its booster lose their effect, the viral load of human immunodeficiency virus (HIV) rises, and the virus may become resistant to treatment (darunavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and darunavir label, US Food and Drug Administration, FDA). A rising viral load shows only on blood tests. The Spanish SmPC of a St John's wort product also lists a fall in levels with possible loss of HIV suppression for protease inhibitors, darunavir among them (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After St John's wort is stopped, darunavir and ritonavir levels may rise (darunavir SmPC, AEMPS).
Management
The combination is contraindicated. St John's wort is on the darunavir contraindication list for both the ritonavir-boosted and the cobicistat-boosted regimen (darunavir summary of product characteristics, SmPC, European Medicines Agency, EMA; darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same contraindication appears in the SmPCs of the darunavir/cobicistat tablets (SmPCs of these products, EMA) and in the US darunavir labels (darunavir label, US Food and Drug Administration, FDA). The Spanish St John's wort product carries the same contraindication: it must not be taken with protease inhibitors, and its interaction table names darunavir (St John's wort SmPC, AEMPS). The authorisation of this product has been suspended since June 2026, and there is no other current Spanish St John's wort SmPC. The EMA monograph contraindicates St John's wort with protease inhibitors for well-established use products, and for traditional use products when the daily hyperforin dose exceeds 1 mg (St John's wort herbal monograph, EMA). The darunavir documents make no such dose exception. If a person is already taking St John's wort, stop it and measure the viral load if possible. After St John's wort is stopped, darunavir and ritonavir levels may rise, and induction may persist for at least 2 weeks (darunavir SmPC, AEMPS). The darunavir documents give no exact interval between stopping St John's wort and starting darunavir, while the herbal monograph says that enzyme activity returns to normal within 1 week (EMA). Before and during darunavir treatment, consider possible interactions and review all concomitant medicines (darunavir FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5